Racial Disparities in Early Lung Cancer Treatment, Outcomes Persist
This video examines racial disparities in treatment and survival outcomes among stage I non–small-cell lung cancer lung cancer patients.
In this video, Andrew Farach, MD, of Houston Methodist Hospital, discusses results of a Surveillance, Epidemiology, and End Results (SEER) database study that examined the outcomes of over 60,000 patients diagnosed with stage I non–small-cell lung cancer (NSCLC) from 2004 to 2012.
The study found that treatment with surgery varied by race of the patient (72%, Asian/Pacific Islander; 67%, Caucasian; 58%, American Indian; and 56%, African-American; P < .05). Survival outcomes at a median follow-up of 23 months varied as well (76%, Asian/Pacific Islander; 70%, Caucasians; 65%, African Americans; and 60% American Indians; P < .05).
Farach presented the results (abstract 9) at the 2017 Multidisciplinary Thoracic Cancers Symposium in San Francisco.
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
